Science Explorer Back to mapMap
Discussion
Institution · Los Angeles Clinical Trials

Most cited papers from Los Angeles Clinical Trials

Los Angeles Clinical Trials

What are the most cited papers from Los Angeles Clinical Trials?

The most cited paper from Los Angeles Clinical Trials is "Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease" (William J. Sandborn, Brian G. Feagan, Paul J. Rutgeerts et al., 2013), with 2,734 citations. Next come "A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation" (1,609) and "Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review" (1,064).

Showing 50 of 59 papers. Every paper with more than 89 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease William J. Sandborn, Brian G. Feagan, Paul J. Rutgeerts et al. · New England Journal of Medicine Open access 21 Aug 2013 2,734
2 A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation Douglas E. Jorenby, Scott James Leischow, Mitchell A. Nides et al. · New England Journal of Medicine Open access 4 Mar 1999 1,609
3 Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review David B. Fogel · Contemporary Clinical Trials Communications Open access 7 Aug 2018 1,064
4 Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease Neil C. Bodick, Walter Offen, Allan I. Levey et al. · Archives of Neurology Apr 1997 697
5 Efficacy and safety of rilonacept (interleukin‐1 trap) in patients with cryopyrin‐associated periodic syndromes: Results from two sequential placebo‐controlled studies Hal M. Hoffman, Martin L. Throne, N. Amar et al. · Arthritis & Rheumatism 30 Jul 2008 584
6 The Safety and Efficacy of Infliximab in Moderate to Severe Chronic Obstructive Pulmonary Disease Stephen I. Rennard et al. · American Journal of Respiratory and Critical Care Medicine 8 Feb 2007 436
7 Smoking Cessation With Varenicline, a Selective α4β2 Nicotinic Receptor Partial Agonist Mitchell A. Nides · Archives of Internal Medicine 14 Aug 2006 396
8 Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial Michel Seymour et al. · The Lancet Oncology Open access 28 May 2013 393
9 The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients Lisheng Liu, Yuqing Zhang, Guozhang Liu et al. · Journal of Hypertension 3 Nov 2005 392
10 Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor Patrick C. May et al. · Journal of Neuroscience Open access 16 Nov 2011 373
11 A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus William A. Fischer, Joseph J. Eron, Wayne Holman et al. · Science Translational Medicine Open access 23 Dec 2021 363
12 Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection Keith S. Kaye et al. · JAMA Open access 27 Feb 2018 314
13 Defining and Assessing Adherence to Oral Antipsychotics: A Review of the Literature D. I. Velligan, Y.-W. F. Lam, David C. Glahn et al. · Schizophrenia Bulletin Open access 12 Oct 2005 310
14 Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients Mark R. Rigby et al. · Journal of Clinical Investigation Open access 20 Jul 2015 294
15 Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis Nadia Mohammed Vashist, Mark Samaan, Mahmoud Hisham Mosli et al. · Cochrane Database of Systematic Reviews Open access 16 Jan 2018 278
16 WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation ® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia Peter John Gilling, Neil J. Barber, Mohamed Bidair et al. · The Journal of Urology 31 Jan 2018 242
17 Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit Ezio Giacobini, René Spiegel, Albert Enz et al. · Journal of Neural Transmission Jul 2002 223
18 Molnupiravir, an Oral Antiviral Treatment for COVID-19 William A. Fischer, Joseph J. Eron, Wayne Holman et al. · medRxiv PreprintOpen access 17 Jun 2021 219
19 The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans Patrick C. May et al. · Journal of Neuroscience Open access 21 Jan 2015 210
20 Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety John J. Sramek, Walter W. Hong, Suha Hamid et al. · Depression and Anxiety ReviewOpen access 1999 185
21 Cholinesterase Inhibitors: A Therapeutic Strategy for Alzheimer Disease Wanda J Krall, John J. Sramek, Neal R. Cutler · Annals of Pharmacotherapy Apr 1999 184
22 Review of the acetylcholinesterase inhibitor galanthamine John J. Sramek, Edyta J. Frackiewicz, Neal R. Cutler · Expert Opinion on Investigational Drugs Oct 2000 182
23 Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons Michael G. Ison et al. · Clinical Infectious Diseases Open access155 authors 22 Jan 2024 176
24 In Vivo, Nucleoside Reverse‐Transcriptase Inhibitors Alter Expression of Both Mitochondrial and Lipid Metabolism Genes in the Absence of Depletion of Mitochondrial DNA Patrick W. G. Mallon, Patrick Unemori, Rebecca Sedwell et al. · The Journal of Infectious Diseases Open access 15 May 2005 171
25 Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder Lev Gertsik, Russell E. Poland, Catherine J. Bresee et al. · Journal of Clinical Psychopharmacology Open access 24 Dec 2011 163
26 Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer Martin George Sanda et al. · JAMA Oncology Open access 18 May 2017 161
27 Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials Jonathan I. Silverberg et al. · The Lancet 24 Jul 2024 156
28 What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It? Aaron S. Kemp, Nina R. Schooler, Amir H Kalali et al. · Schizophrenia Bulletin Open access 22 Aug 2008 150
29 PCA3 Molecular Urine Test as a Predictor of Repeat Prostate Biopsy Outcome in Men with Previous Negative Biopsies: A Prospective Multicenter Clinical Study MARC C. GITTELMAN, Bernard Hertzman, James L. Bailen et al. · The Journal of Urology 15 Feb 2013 148
30 Histologic scoring indices for evaluation of disease activity in ulcerative colitis Mahmoud Hisham Mosli, Claire E. Parker, Sigrid Nelson et al. · Cochrane Database of Systematic Reviews Open access 25 May 2017 146
31 Pramipexole in Patients with Early Parkinsonʼs Disease Jean Pintar Hubble, William C. Koller, Neal R. Cutler et al. · Clinical Neuropharmacology Aug 1995 146
32 Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: A randomized placebo‐controlled study David H. Gonzales, Mitchell A. Nides, Linda Hyder Ferry et al. · Clinical Pharmacology & Therapeutics Jun 2001 145
33 Rizatriptan (MAXALT) for the Acute Treatment of Migraine and Migraine Recurrence. A Placebo‐Controlled, Outpatient Study Judith Teall, Michael M. Tuchman, Neal R. Cutler et al. · Headache The Journal of Head and Face Pain Apr 1998 143
34 Celecoxib Augmentation of Continuously Ill Patients with Schizophrenia Mark Hyman Rapaport, Katia K Delrahim, Catherine J. Bresee et al. · Biological Psychiatry 17 May 2005 139
35 Galantamine hydrobromide: An agent for Alzheimer’s disease Victoria Zarotsky, John J. Sramek, Neal R. Cutler · American Journal of Health-System Pharmacy Mar 2003 138
36 Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD Sophie Van Welden, Andrew C. Selfridge, Pieter Hindryckx · Nature Reviews Gastroenterology & Hepatology Review 30 Aug 2017 132
37 Use of a Simple Criteria Set for Guiding Echocardiography in Nosocomial Staphylococcus aureus Bacteremia Achim Jens Kaasch, Vance G. Fowler, Siegbert Rieg et al. · Clinical Infectious Diseases Open access 7 Jun 2011 132
38 Update on Pharmacologic Options for Smoking Cessation Treatment Mitchell A. Nides · The American Journal of Medicine 14 Mar 2008 132
39 Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients Gilbert Y. Lefèvre, Greg Sedek, S. S. Jhee et al. · Clinical Pharmacology & Therapeutics 23 May 2007 132
40 Nicotine Blood Levels and Short-term Smoking Reduction with an Electronic Nicotine Delivery System Mitchell A. Nides, Scott James Leischow, Meghna Bhatter et al. · American Journal of Health Behavior 15 Nov 2013 130
41 Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: Results of two randomized, investigator-blinded, multicenter, international, controlled trials∗ Boni Elizabeth Elewski, Héctor Cáceres, Liberation DeLeon et al. · Journal of the American Academy of Dermatology 19 Apr 2008 129
42 Gender Differences in Depression and Antidepressant Pharmacokinetics and Adverse Events Edyta J Frackiewicz, John J. Sramek, Neal R. Cutler · Annals of Pharmacotherapy 2000 124
43 Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease Neal R. Cutler, R. J. Polinsky, J. J. Srarnek et al. · Acta Neurologica Scandinavica 29 Jan 2009 122
44 Aripiprazole for the treatment of pediatric bipolar I disorder: a 30‐week, randomized, placebo‐controlled study Robert L. Findling, Christoph Ulrich Correll, Margaretta Nyilas et al. · Bipolar Disorders 25 Feb 2013 122
45 Pharmacokinetics and Pharmacodynamics of the Triptan Antimigraine Agents Stanford S. Jhee, Thomas M. Shiovitz, Aaron W. Crawford et al. · Clinical Pharmacokinetics 2001 121
46 Smoking reduction and the rate of decline in FEV1: results from the Lung Health Study M Simmons, John E. Connett, Mitchell A. Nides et al. · European Respiratory Journal Open access Jun 2005 120
47 Avotermin for Scar Improvement following Scar Revision Surgery: A Randomized, Double-Blind, Within-Patient, Placebo-Controlled, Phase II Clinical Trial Karen So, Duncan Angus McGrouther, JAMES A. BUSH et al. · Plastic & Reconstructive Surgery 25 Jun 2011 113
48 Capsaicin-evoked Mechanical Allodynia and Hyperalgesia Cross Nerve Territories Christine Nai-Mei Sang, Richard H. Gracely, Mitchell B. Max et al. · Anesthesiology Sep 1996 113
49 Efficacy and Safety of Doxepin 1 mg, 3 mg, and 6 mg in Elderly Patients With Primary Insomnia Martin B. Scharf, Roberta Rogowski, Steven G. Hull et al. · The Journal of Clinical Psychiatry 31 Oct 2008 111
50 Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study Sheldon Morris, Claire Bristow, Michael R. Wierzbicki et al. · The Lancet Infectious Diseases Open access 23 Nov 2020 110

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.